Notes

Slide Show

Outline

1	RESIST Trials - Grade 3 or 4 AST, ALT or Total Bilirubin: Actions and Outcomes
2	Lipid Lowering Agent Use Among RESIST Participants
3	Effect of LLD on triglycerides: RESIST
4	Risk Confirmed (3 times) Triglycerides Above 500 mg/dl for RESIST Patients
5	RTV-boosted drug interaction assessments
6	Reduced GSS as Key Mutations Increase
7	Hypertriglyceridemia: Relative Contribution of TPV and RTV
8	Analysis of Treatment Response at Week 48
9	K-M Probabilities for Grade 3 or 4 ALT and/or AST Through 120 Weeks in 8 HIV+ Integrated Trials*
10	RESIST Studies Cox Regression Model for Risk of Grade 3 or 4 ALT/AST
11	Predictors of TPV/r Antiviral Response Multiple Regression Model
12	Tipranavir trough concentrations with proton pump inhibitors
13	Trial 1182.52 Impact of IQ on 14-Day Viral Load Response
14	1182.52 Impact of IQ on 14-Day Viral Load Response
15	RESIST Trials 24 Week VL Change according to IQ in Patients not using Enfuvirtide
16	RESIST Trials 24 Week VL Change according to IQ in Patients using Enfuvirtide
17	Antiviral activity of tipranavir (ViroLogic) Non-clade B isolates
18	VIRCO / ViroLogic in Tipranavir Phenotype
19	Mutations Which Increase Susceptibility to TPV